Obesity with insulin resistance increase thrombosis in wild-type and bone marrow-transplanted Zucker fatty rats

Thrombosis and Haemostasis

Volumn 109, Issue 2, 2013, Pages 319-327

  Vera, Rodrigo Hernández ^a   Vilahur, Gemma ^a   Badimon, Lina ^a,b  

^a CSIC   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Bone marrow; Insulin resistance; Obesity; Thrombosis

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ENROFLOXACIN; FIBRINOGEN; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME IMMUNOASSAY; HEMATOLOGICAL PARAMETERS; INSULIN RESISTANCE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; RISK; THROMBOCYTE COUNT; THROMBOSIS; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; BLOOD PLATELETS; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CELL SIZE; DISEASE MODELS, ANIMAL; INSULIN; INSULIN RESISTANCE; OBESITY; PLATELET COUNT; PROTHROMBIN TIME; RATS; RATS, ZUCKER; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS;

EID: 84874690590     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-09-0696     Document Type: Article

References (41)

1. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. J Am Med Assoc 2003; 289: 187-193.
2. Hu FB, Willett WC, Li T, et al. Adiposity as Compared with Physical Activity in Predicting Mortality among Women. N Engl J Med 2004; 351: 2694-2703.
3. Poirier P, Giles TD, Bray GA, et al. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss. Circulation 2006; 113: 898-918.
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
5. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-233.
6. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-1932.
7. Alberti KG, Eckel RH, Grundy SM, et al. Harmonising the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
8. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
9. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother 2011; 12: 1887-1900.
10. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904.
11. Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540.
12. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-429.
13. Alessi MC, Lijnen HR, Bastelica D, et al. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2003; 33: 290-297.
14. McDermott MM, Green D, Greenland P, et al. Relation of levels of haemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003; 92: 194-199.
15. Reiner AP, Siscovick DS, Rosendaal FR. Haemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-595.
16. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
17. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
18. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
19. Higdon JV, Frei B. Obesity and oxidative stress: a direct link to CVD? Arterioscler Thromb Vasc Biol 2003; 23: 365-367.
20. Oñate B, Vilahur G, Ferrer-Lorente R, et al. The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. FASEB J 2012; 26: 4327-4336.
21. Nilsson C, Raun K, Yan F-F., et al. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin 2012; 33: 173-181.
22. Phillips MS, Liu Q, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996; 13: 18-19.
23. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med 1997; 214: 222-232.
24. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
25. Hernández Vera R, Vilahur G, Ferrer-Lorente R, et al. Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 2141-2148.
26. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-161.
27. Greisenegger S, Endler G, Hsieh K, et al. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004; 35: 1688-1691.
28. Martin JF, Trowbridge EA, Salmon G, et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
29. Bavbek N, Kargili A, Kaftan O, et al. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy? Clin Appl Thromb Haemost 2007; 13: 391-397.
30. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 2005; 57 (Suppl): 42-58.
31. Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17: 47-58.
32. Ishibashi T, Kimura H, Uchida T, et al. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 1989; 86: 5953-5957.
33. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-3347.
34. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
35. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001; 21: 968-970.
36. Nicoletti G, Giugliano G, Pontillo A, et al. Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. J Endocrinol Invest 2003; 26: RC5-8.
37. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
38. van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999; 19: 672-679.
39. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
40. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105 (Suppl) 1: S43-54.
41. Vazzana N, Ranalli P, Cuccurullo C, et al. Diabetes mellitus and thrombosis. Thromb Res 2012; 129: 371-377.